title: Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
abstract: In this study, we utilized a conditioning regimen with fludarabine and myeloablative dose i.v. BU (12.8 mg/kg) (FluBU) in 36 adult patients (median age: 44 years, range: 18-61) with myeloid or lymphoid malignancies at standard risk (n=10) or high risk of relapse (n=26), who received an allogeneic hematopoietic SCT (HSCT) from HLA-matched related (n=16) or unrelated (n=20) donors. The source of hematopoietic stem cells was peripheral blood in 28 and marrow in 8 cases. Rabbit-antithymocyte globulin at 7 mg/kg was utilized in 21 patients. Acute GVHD grade II-IV was observed in 19% of the patients (grade III-IV in 14% of patients) and chronic GVHD in 11 of 30 evaluable patients (37%). At median follow-up of 737 days (range: 152-1,737) for alive patients, overall survival rates in standard- and high-risk patients were 80 and 35%, respectively, and event-free survival rates were 70 and 31%, respectively. TRM was 10% in standard-risk and 19% in high-risk patients. Post transplant relapse was observed in 20% standard-risk and in 46% high-risk patients. FluBU conditioning regimen is associated with a limited hematologic and extrahematologic toxicity and with an antitumor activity comparable to other standard myeloablative regimens.
authors.affiliation: Stem Cell Transplant Program, Section of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chunduri
authors.forename: L C
authors.initials: LC
authors.lastname: Dobogai
authors.forename: D
authors.initials: D
authors.lastname: Peace
authors.forename: Y
authors.initials: Y
authors.lastname: Saunthararajah
authors.forename: J
authors.initials: J
authors.lastname: Quigley
authors.forename: Y-H
authors.initials: YH
authors.lastname: Chen
authors.forename: N
authors.initials: N
authors.lastname: Mahmud
authors.forename: E
authors.initials: E
authors.lastname: Hurter
authors.forename: R
authors.initials: R
authors.lastname: Beri
authors.forename: D
authors.initials: D
authors.lastname: Rondelli
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods*; D002066:Busulfan / Q000008:administration & dosage*; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007262:Infusions, Intravenous; D007938:Leukemia / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage*; D009190:Myelodysplastic Syndromes / Q000628:therapy; D011446:Prospective Studies; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D019653:Myeloablative Agonists; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine